| Literature DB >> 32260538 |
Nansi López-Valverde1, Jorge Muriel Fernández1, Antonio López-Valverde1, Luis F Valero Juan2, Juan Manuel Ramírez3, Javier Flores Fraile1, Julio Herrero Payo1, Leticia A Blanco Antona1, Bruno Macedo de Sousa4, Manuel Bravo5.
Abstract
BACKGROUND: Dental treatments often cause pain and anxiety in patients. Virtual reality (VR) is a novel procedure that can provide distraction during dental procedures or prepare patients to receive such type of treatments. This meta-analysis is the first to gather evidence on the effectiveness of VR on the reduction of pain (P) and dental anxiety (DA) in patients undergoing dental treatment, regardless of age.Entities:
Keywords: dental anxiety; distraction systems; pain; virtual reality
Year: 2020 PMID: 32260538 PMCID: PMC7231096 DOI: 10.3390/jcm9041025
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Increasing tendency of publications, according the U.S. National Library of Medicine database, using “dental phobia” as the keyword.
Checklist of Reporting of Observational studies in Epidemiology (STROBE) criteria reported by the included studies. Each item was judged as “0” (not reported) or “1” (reported). The total score of each of included studies was also recorded.
| Authors | Asl Aminabadi et al. [ | Tanja-Dijkstra et al. [ | Nunna et al. [ | Gujjar et al. [ | Niharika et al. [ | Al-Halabi et al. [ | Raghav et al. [ | Tanja-Dijkstra et al. [ | Shetty et al. [ | Al-Khotani et al. [ | Mitrakul et al. [ | Asvanund et al. [ | Bentsen et al. [ | Sweta et al. [ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Section and item | ||||||||||||||
| 1. Title and Abstract | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Introduction | ||||||||||||||
| 2. Background | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 3. Objectives | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Methods | ||||||||||||||
| 4. Study design | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 5. Setting | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| 6. Participants | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 7. Variables | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 8. Data sources/ Measurement | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 9. Bias | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| 10. Study Size | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 11.Quantitative variables | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 12. Statistical Methods | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Results | ||||||||||||||
| 13. Participants | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 14. Descriptive data | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 15. Outcome data | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 16. Main results | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 17. Other analyses | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 |
| Discussion | ||||||||||||||
| 18. Key results | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 19. Limitations | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| 20. Interpretation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 21. Generalisability | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Other information | ||||||||||||||
| 22. Funding | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total score | 21 | 19 | 20 | 20 | 20 | 22 | 20 | 18 | 20 | 21 | 22 | 20 | 21 | 20 |
Mode Value: 27.4 (± 0.85).
Figure 2Flow chart of the study selection process. PRISMA (Preferred Reporting Items for Systematic Review and meta Analyses) [16].
Details of each study.
| Study | Journal | Children Values (Ma, | Adult Values (Ma, | Dental Procedure | VR Device Equipment | Measuring Scales | Outcomes | |
|---|---|---|---|---|---|---|---|---|
| DA | P | |||||||
| Asl Aminabadi et al. 2012 [ | J Dent Res Dent Clin Dent Prospect | Ma = 5.4 | Restorative treatment in primary molars. | I-glasses 920HR Ilixco, Inc. Menlo Park, CA, USA. | MDAS | W-BFS | There was a significant decrease in pain perception and anxiety scores with the use of VR eyeglasses during dental treatment. | |
| Tanja-Dijkstra et al 2014 [ | Plos One J | Ma = 33.1 | A simulated dental treatment. | Eyeglasses EVuzix iWear VR920 headset. Dual-core, 1.3GHz Intel processor with Nvidia GT | MDAS | Participants with higher | ||
| Nunna et al 2019 [ | J Dent Anesth Pain Med | Ma = Nr | - Counter-stimulation. | Lenovo smartphone, Sennheiser earphones, and ANTVR glasses. | VCARS | W-BFS | Assessment of mean anxiety scores showed a significant difference in girls belonging to the VR group. | |
| Gujjar et al. 2019 [ | Journal of Anxiety Disorders | Ma = group 1, 25.3 | Routine dental | Eyeglasses. Dell XPS-8700 desktop with 4th Generation | MDAS | VAS | The results of this study provide evidence to support the efficacy of | |
| Niharika et al. 2018 [ | J Indian Soc Pedod Prev Dent | Ma = Group A (7.17 ± 0.316) | Routine dental care | Google VR Box and Anti-Tank Virtual Reality 3D Glasses | MDAS | W-BFS | Two groups. Childhood Anxiety-Related Disorders scores did not differ significantly between the two groups. | |
| Al-Halabi et al. 2018 [ | Anaesth Pain & Intensive Care | Ma = 7.4 | Local anaesthesia in mandibular arch (inferior alveolar nerve block). | Eyeglasses | W-BFS | Three groups. There was no significant difference in the anxiety of groups. There was a statistically significant difference in the anxiety and pain level in pulse rate. | ||
| Raghav et al. 2016 [ | BMC Oral Health J | Ma = Nr | 1. Restorative dental procedure which may or may not be requiring local anaesthesia. | Oculus development kit 2HMD, with a resolution of | MDAS | VAS | Two groups, VR (Idle, Mirror, Syringe, | |
| Tanja-Dijkstra et al. 2014 [ | Trials J | Ma = Nr | Dental treatment | Eyeglasses. | MDAS | This study compared two types of VR, natural environment and urban environment. | ||
| Shetty et al. 2019 [ | The Journal of Clinical Paediatric Dentistry | Ma = Nr | Dental treatment | Eyeglasses. | MDAS | W-BFS | Two groups. The group with VR distraction, reported a decrease in the severity of anxiety. | |
| Al-Khotani et al. 2016 [ | Acta Odontologica Scandinavica | Ma = 8.2 | Dental examination, oral hygiene information, prophylaxis, restorative treatment. | Eyeglasses. | MDAS | Two groups. VR and control group. Significant reduction in anxiety throughout the restorative procedure (including injection with local anaesthesia) in VR group. | ||
| Mitrakul et al. 2015 [ | European Journal of Paediatric Dentistry | Ma = 6.9 ± 0.9 | Restorative dental treatment in maxilla or mandible under local anaesthetic | Eyeglasses. (Shenzhen Longway Vision Technology Co. Ltd, Shenzhen, China). | FPS-R | FLACC | Two groups. | |
| Asvanund et al. 2015 [ | Quintessence International | Ma= 7 ± 0.8 | Restorative dental | Eyeglasses (Shenzhen Longway Vision Technology | FPS-R | FLACC | Two groups. | |
| Bentsen et al. 2001 [ | Eur J of Pain- London | Ma = Nr | Dental treatment | Video glasses | VAS | The study was a split-mouth, randomized design (2 dental filling). Dental treatments were performed without anaesthesia. | ||
| Sweta et al. 2019 [ | Ann Maxillofac Surgery | Ma = 39.72 ± 15.93. | Local anaesthesia in patients undergoing a dental procedure. | Nr | NCAQ | Local anaesthesia and extractions reported the highest anxiety levels among the patients. | ||
n (Participant number); Ma (Mean age years); Ar (Age range years); Nr (Not reported); VAS (Visual Analogic Scale); W–BFS (Wong–Baker Faces Scale); FPS-R (Faces Pain Scale-Revised); FLACC (Consolability Scale); VRS (Verbal Rating Scale); MDAS (Modified Dental Anxiety Scale); NCAQ (Norman Corah’s anxiety questionnaire); VCARS (Venham’s Clinical Anxiety Rating Scale). DA (Dental Anxiety); P (Pain).
Figure 3Risk of bias.
Figure 4Forest plot for anxiety in Children.
Figure 5Forest plot for Anxiety in Adults.
Meta-analysis of anxiety. Characteristics of individual studies and meta-analysis. a: Standardized difference of means.
| Age group/Study | Year | Scale | Test | Control | SMDa | Heterogeneity | Public.bias | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Mean ± sd |
| Mean ± sd | Weight | Mean | 95%-CI | ||||||
| Children + Adults ( | 282 | 284 | −0.54 | −1.58 to 0.49 | 0.302 | 31% ( | ||||||
| Children ( | ||||||||||||
| Shetty V2 [ | 2019 | MDAS | 60 | 11.3 ± 3.5 | 60 | 16.5 ± 3.5 | 14.6% | −1.48 | −1.88 to −1.07 | |||
| Nunna M1 [ | 2019 | VCARS | 35 | 0.57 ± 0.61 | 35 | 1.00 ± 0.84 | 14.5% | −0.58 | −1.06 to −0.10 | |||
| Niharika P1 [ | 2018 | MDAS | 20 | 19.6 ± 0.9 | 20 | 17.3 ± 0.8 | 13.8% | 2.74 | 1.86 to 3.63 | |||
| Mitrakul K2 [ | 2015 | FLACC | 21 | 26.0 ± 9.1 | 21 | 28.0 ± 12.0 | 14.3% | −0.18 | −0.79 to 0.43 | |||
| Mitrakul K1 [ | 2015 | FLACC | 21 | 29.5 ± 11.3 | 21 | 27.3 ± 10.6 | 14.3% | 0.20 | −0.41 to 0.80 | |||
| Asl Aminabadi N1 [ | 2012 | MDAS | 60 | 12.6 ± 1.0 | 60 | 17.7 ± 1.2 | 14.2% | −4.46 | −5.14 to −3.78 | |||
| Al-Khotani A [ | 2016 | MDAS | 28 | 0.14 ± 0.36 | 28 | 0.75 ± 0.52 | 14.3% | −1.34 | −1.93 to −0.76 | |||
| Total | 245 | 245 | 100% | −0.74 | −1.99 to 0.51 | 0.243 | 38% ( | |||||
| Adults ( | ||||||||||||
| Tanja-Dijkstra K [ | 2014 | MDAS | 22 | 3.73 ± 0.65 | 24 | 3.33 ± 0.87 | 54.6% | 0.51 | −0.08 to 1.10 | |||
| Gujjar KR1 [ | 2019 | MDAS | 15 | 18.3 ± 2.6 | 15 | 18.8 ± 2.8 | 45.4% | −0.18 | −0.90 to 0.54 | |||
| Total | 37 | 39 | 0.20 | −0.48 to 0.87 | 0.567 | 0% ( | - | |||||
Figure 6Forest plot for pain in Children.
Figure 7Forest plot for Pain in Adults.
Meta-analysis of pain according to random effect models. Characteristics of individual studies and meta-analysis. a: Standardized difference of means.
| Age group/Study | Year | Scale | Test | Control | SMDa | Heterogeneity | Public.bias | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Mean ± sd | n | Mean ± sd | Weight | Mean | 95%-CI | ||||||
| Children + Adults ( | 355 | 355 | −0.77 | −1.28 to −0.26 | 0.003 | 65.8% (0.002) | 0.173 | |||||
| Children ( | ||||||||||||
| Shetty V1 [ | 2019 | W-BFS | 60 | 2.00 ± 0.50 | 60 | 2.42 ± 1.47 | 13.6% | −0.38 | −0.74 to −0.0 | |||
| Nunna M2 [ | 2019 | W-BFS | 35 | 3.03 ± 2.22 | 35 | 2.97 ± 2.49 | 13.2% | 0.03 | −0.44 to 0.49 | |||
| Niharika P2 [ | 2018 | W-BFS | 20 | 2.56 ± 0.39 | 20 | 5.22 ± 0.51 | 7.8% | −5.71 | −7.16 to −4.25 | |||
| Mitrakul K4 [ | 2015 | FPS-R | 21 | 1.90 ± 2.93 | 21 | 1.90 ± 3.32 | 12.5% | 0.00 | −0.60 to 0.60 | |||
| Mitrakul K3 [ | 2015 | FPS-R | 21 | 0.86 ± 1.49 | 21 | 1.62 ± 2.94 | 12.5% | −0.32 | −0.93 to 0.29 | |||
| Asvanund Y2 [ | 2015 | FPS-R | 49 | 2.23 ± 2.29 | 49 | 2.46 ± 3.46 | 13.5% | −0.08 | −0.47 to 0.32 | |||
| Asvanund Y1 [ | 2015 | FPS-R | 49 | 1.57 ± 2.29 | 49 | 3.04 ± 3.08 | 13.5% | −0.54 | −0.94 to −0.13 | |||
| Asl Aminabadi N2 [ | 2012 | W-BFS | 60 | 1.89 ± 0.65 | 60 | 3.00 ± 0.81 | 13.4% | −1.50 | −1.91 to −1.10 | |||
| Total | 315 | 315 | 100% | −0.82 | −1.42 to −0.22 | 0.008 | 71% ( | |||||
| Adults ( | ||||||||||||
| Sweta VR [ | 2019 | VAS | 25 | 1.28 ± 0.89 | 25 | 2.60 ± 1.38 | 52.3% | −1.12 | −1.72 to −0.52 | |||
| Gujjar KR2 [ | 2019 | VAS | 15 | 68 ± 10 | 15 | 70 ± 14 | 47.7% | −0.18 | −0.90 to 0.53 | |||
| Total | 40 | 40 | −0.67 | −1.58 to 0.24 | 0.149 | 0% ( | - | |||||